---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-015642"
form_type: "8-K"
ticker: "PPCB"
cik: "0001517681"
company_name: "Propanc Biopharma, Inc."
filed_at: "2025-06-18T23:59:59+00:00"
generated_at: "2026-05-19T02:51:36.705905+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Propanc Biopharma enters $25K convertible note and $13K AUD loan for working capital

## Summary
- Issued $25,000 convertible note to Geebis Consulting at 8% interest; maturity June 2026; conversion price $5.00.
- Note sold at $22,500 (10% OID); prepayment options with premiums from 110% to 125% within first 180 days.
- Received $13,188 AUD loan from board member at 12% interest, maturing June 30, 2025.
- Proceeds from both financings will be used for general working capital purposes.
- Note is subject to 4.99% beneficial ownership limitation; conversion price adjusts on default.

## SEC filing metadata
- accession: 0001641172-25-015642
- form_type: 8-K
- ticker: PPCB
- cik: 0001517681
- company_name: Propanc Biopharma, Inc.
- filed_at: 2025-06-18T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517681/000164117225015642/0001641172-25-015642-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517681/000164117225015642/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-015642
- JSON: https://secwatch.observer/filing/0001641172-25-015642.json
- Plain text: https://secwatch.observer/filing/0001641172-25-015642.txt

## Key facts
- Debt Financings
  Propanc Biopharma, Inc. incurred loan of $13,188 AUD with one of our members of the Board of Directors (the “Board Member”) at 12% per annum maturing June 30, 2025.
  - Instrument: loan
  - Principal: $13,188 AUD
  - Counterparty: one of our members of the Board of Directors (the “Board Member”)
  - Rate: 12% per annum
  - Maturity: June 30, 2025
  - Event: incurrence
  source text: Effective Junel 13, 2025, the Company entered into and closed a loan agreement (the “Loan”) with one of our members of the Board of Directors (the “Board Member”), pursuant to which the Board Member loaned the Company an aggregate principal amount of $13,188 AUD.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000164117225015642/0001641172-25-015642-index.htm
- Debt Financings
  Propanc Biopharma, Inc. incurred convertible notes of $25,000 with an investor at 8% per annum maturing June 12, 2026.
  - Instrument: convertible notes
  - Principal: $25,000
  - Counterparty: an investor
  - Rate: 8% per annum
  - Maturity: June 12, 2026
  - Event: incurrence
  source text: Effective June 12, 2025, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $25,000 (the “Note”), for a purchase price of $22,500.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000164117225015642/0001641172-25-015642-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.